Enterprise Value
30.49M
Cash
40.94M
Avg Qtr Burn
-14.71M
Short % of Float
1.91%
Insider Ownership
0.08%
Institutional Own.
39.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eblasakimab (ASLAN004) (IL-13Ra1 inhibitor) Details Atopic dermatitis | Phase 3 Initiation | |
EblasaKimab Details Atopic dermatitis | Phase 2 Data readout | |
Farudodstat (ASLAN003) (DHODH inhibitor) Details Autoimmune disease, Alopecia areata | Phase 2a Data readout |